Pfizer Settles Off-Label Marketing Claims
January 27, 2009 · Print This Article
Margaret Cronin Fisk of Bloomberg News has reported that Pharmaceutical giant Pfizer Inc. has agreed to pay $2.3 billion to resolve inquiries into allegations that the drug maker improperly marketed the painkiller Bextra and other drugs. In a statement released yesterday, the company said the settlement would tentatively cover all government investigations into off-label marketing practices. Earlier this month, Eli Lilly & Co. agreed to pay $1.42 billion to settle similar claims over its antipsychotic drug Zyprexa.
The settlement is the largest for claims of off-label marketing practice.
If you have been injured by medical malpractice, by taking a medication, or by a medical device, please call Ed Wallis at (901) 527-2125 for a free case evaluation, or fill out this form:
Comments
Got something to say?